Table 7.
Numerical and percentage distribution of ligand/VEGFR-2 and VEGFR-2/pVEGFR-2 co-expression in the vasculature
| N0/M0 | N+ | M+ | ||
|---|---|---|---|---|
| n (%) | n (%) | n (%) | ||
| VEGF-C+/VEGFR-2+ | ||||
| Capillaries | zone 1 | 20/8 (40) | 9/6 (67) | 9/6 (67) |
| zone 2 | 16/16 (100) | 11/11 (100) | 11/9 (82) | |
| zone 3 | 18/11 (61) | 13/11 (85) | 16/14 (88) | |
| Small vessels | zone 1 | 16/12 (75) | 11/6 (55) | 15/8 (53) |
| zone 2 | 23/21 (91) | 16/15 (94) | 17/14 (82) | |
| zone 3 | 17/9 (53) | 14/8 (57) | 13/7 (54) | |
| VEGF-D+/VEGFR-2+ | ||||
| Capillaries | zone 1 | 11/10 (91) | 8/7 (88) | 9/8 (89) |
| zone 2 | 19/19 (100) | 11/11 (100) | 15/14 (93) | |
| zone 3 | 21/15 (71) | 14/12 (86) | 12/12 (100) | |
| Small vessels | zone 1 | 10/9 (90) | 6/4 (67) | 8/5 (63) |
| zone 2 | 27/24 (89) | 17/16 (94) | 19/17 (89) | |
| zone 3 | 26/16 (62) | 19/11 (58) | 15/10 (67) | |
| VEGFR-2+/VEGFR-2 Tyr1175 + | ||||
| Capillaries | zone 1 | 20/17 (85) | 14/14 (100) | 12/10 (83) |
| zone 2 | 34/31 (91) | 21/19 (90) | 18/15 (83) | |
| zone 3 | 22/22 (100) | 18/17 (94) | 19/18 (95) | |
| Small vessels | zone 1 | 13/10 (77) | 8/8 (100) | 11/9 (82) |
| zone 2 | 29/26 (90) | 20/18 (90) | 16/14 (88) | |
| zone 3 | 18/16 (89) | 12/12 (100) | 9/8 (89) | |
| VEGFR-2+/VEGFR-2 Tyr1214 + | ||||
| Capillaries | zone 1 | 19/18 (95) | 13/10 (77) | 14/13 (93) |
| zone 2 | 33/32 (97) | 21/19 (90) | 21/21 (100) | |
| zone 3 | 21/21 (100) | 15/15 (100) | 21/21 (100) | |
| Small vessels | zone 1 | 15/14 (93) | 8/6 (75) | 11/10 (91) |
| zone 2 | 27/27 (100) | 20/19 (95) | 19/19 (100) | |
| zone 3 | 17/17 (100) | 12/11 (92) | 12/12 (100) | |
n: total number of ligand positive cases / total number of ligand positive cases with concomitant VEGFR-2 positivity or total number of VEGFR-2 positive cases / total number of VEGFR-2 positive cases with concomitant pVEGFR-2 positivity. There were no significant differences between the groups